Nvidia posted record $68.1 billion Q4 revenue and $43B net income, driven by data center AI demand, and guided $78B revenue ...

Novo Nordisk (NVO) is upgraded to 'Hold' as its market cap returns to pre-GLP-1 mania levels, limiting further downside. NVO ...

When you click on “Accept all”, you consent to ads on this site being customized to a personal profile we or our advertising partners may have about you. Choose “Customize or Reject all” if you want ...

Management expects total revenues for 2026 between $1.22 billion and $1.28 billion, with NUPLAZID net sales projected at $760 million to $790 million and DAYBUE net sales expected between $460 million ...

Hey folks, Pop Mart's Labubu exploded in 2025 with global sales topping 100 million units, helping drive total IP sales past ...

The popularity of the medication is boosting sales in hair and beauty products at the pharmacies giant, and a new oral version will drive demand even higher.

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and Rybelsus, by up to 50 percent beginning next year. Starting on Jan. 1, ...

The winners will not be those who merely predict cliffs, but those who re-architect early enough. Merck’s oncology spin-out underscores a defining reality of modern pharma: molecules may create value, ...

West Conshohocken's Madrigal Pharmaceuticals’ flagship drug Rezdiffra nearly reached blockbuster status, bringing in $958.4 ...

For years, the gap between traditional finance and cryptocurrency felt wide, full of uncertainty and hesitation. But that’s ...

Trump increased the rate of a new global tariff to 15 percent, vowing to work around the ruling that invalidated his ...